Clinical Trials Logo

Clinical Trial Summary

This observational prospective study will help to determine if an immune process similar to allograft rejection is responsible for the occurrence of an intrahepatic cholestasis of pregnancy (ICP). If so, it would suggest the potential benefit of immunomodulatory therapeutics.


Clinical Trial Description

This observational study will include 322 pregnant women at delivery: 161 women diagnosed with an intrahepatic cholestasis of pregnancy, and 161 control women. A blood test will be performed at delivery for each woman and each newborn, in order to measure several biological parameters involved in inflammation processes, allograft rejection and angiogenesis. Placenta will also be analysed. In particular, we will look for chronic inflammation in placenta. Biological parameters and placental parameters will be compared between the two groups: cases with ICP and controls. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05197387
Study type Observational
Source University Hospital, Brest
Contact Claire de Moreuil
Phone 02 98 14 53 03
Email claire.demoreuil@chu-brest.fr
Status Recruiting
Phase
Start date June 21, 2022
Completion date June 21, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04281082 - Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives
Recruiting NCT03519399 - Bile Acid Effects in Fetal Arrhythmia Study